TMED3 and prostate carcinoma: In order to illustrate the potential of the selected putative targets in the treatment of hormone-refractory disease, the efficacy of AIM1, ERGIC1, TMED3, and TPX2 silencing in the inhibition of prostate cancer cells cultured in androgen deprived conditions was studied.